Vor Ort
Merkzettel Warenkorb
  • Produktbild: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
  • Produktbild: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
Band 112

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989

Aus der Reihe Developments in Cardiovascular Medicine

148,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.10.2011

Herausgeber

J. Morganroth + weitere

Verlag

Springer Us

Seitenzahl

230

Maße (L/B/H)

23,5/15,5/1,4 cm

Gewicht

376 g

Auflage

Softcover reprint of the original 1st ed. 1990

Sprache

Englisch

ISBN

978-1-4612-8809-1

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.10.2011

Herausgeber

Verlag

Springer Us

Seitenzahl

230

Maße (L/B/H)

23,5/15,5/1,4 cm

Gewicht

376 g

Auflage

Softcover reprint of the original 1st ed. 1990

Sprache

Englisch

ISBN

978-1-4612-8809-1

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
  • Produktbild: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
  • I. Approaches and Methods to Studying Antihypertensive Drugs.- 1. New concepts in antihypertensive drug therapy.- 2. Is ambulatory blood pressure monitoring required to define the hypertensive patient and to detect efficacy?.- 3. What vascular effects should be measured in antihypertensive drug research?.- 4. Is it necessary to demonstrate changes in left ventricular hypertrophy in the evaluation of antihypertensive drugs?.- 5. Clinical trials of antihypertensive agents.- 6. How does one define dose-duration of an antihypertensive drug? What is the role of non-Mem and the Peak/Through measurement.- Panel Discussion on Hypertension Methodology.- II. What Should be Required for FDA Approvability of a New Antihypertensive Drug?.- 7. What have we learned from prior clinical trials of antihypertensive drug therapy?.- 8. Are specific studies in elderly patients required for FDA approvability of a new antihypertensive drug?.- 9. Do we need any more antihypertensive drugs: The validity of a change in blood pressure as the only endpoint for approvability?.- 10. The cost and time to develop a new antihypertensive drug depending upon the endpoint.- Panel Discussion on Hypertensive Trial Design Issues.- III. Surrogate Endpoints to Define Risk VS. Benefits.- 11. What should be required for FDA approvability of a new antihypertensive drug? What is the FDA’s viewpoint?.- 12. Are there valid surrogate endpoints for mortality that can be used to evaluate the effects of antiarrhythmic drug therapy?.- Panel Discussion on Surrogate Endpoints: Antiarrhythmic Agents.- 13. How to demonstrate the efficacy of a new drug for the treatment of chronic heart failure.- Panel Discussion on Surrogate Endpoints: Congestive Heart Failure Agents.- 14. Testing the relationship between cholesterol lowering and cardiovascular disease — past, present, and prospects.- Panel Discussion on Surrogate Endpoints: Hypolipidemic Agents.- Participant List.